Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $8.09, but opened at $8.84. Pharming Group shares last traded at $8.47, with a volume of 230 shares trading hands.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on PHAR. Oppenheimer lifted their target price on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th.
View Our Latest Report on Pharming Group
Pharming Group Trading Down 0.9 %
The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average of $8.44 and a 200-day moving average of $8.68. The stock has a market cap of $578.26 million, a PE ratio of -32.69 and a beta of -0.08.
Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. On average, analysts anticipate that Pharming Group will post -0.2 EPS for the current year.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
